Two cases of idiopathic chondrolysis were treated by botulinum neurotoxin-A injections, with a favorable outcome. The treatment consisted of botulinum neurotoxin-A injections, followed by an intensive rehabilitation program. No surgery was needed. Both patients were symptom-free and showed an extremely satisfactory range of motion. Radiographs indicated reconstitution of the joint space in both cases. We believe that botulinum neurotoxin-A injections combined with an intensive rehabilitation program may be considered a new potential management modality and is worth attempting and studying when one considers the results of previously published reports.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/BPB.0000000000000076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Safety and efficacy of Relatox in comparison with Dysport in the treatment of focal spasticity of the upper limb in patients after stroke and traumatic brain injury (results of a prospective simple blind randomized comparative study in parallel groups)].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
GUTA-CLINIC LLC, Moscow, Russia.
Article Synopsis
- The study aimed to evaluate the safety and effectiveness of Relatox, a type of botulinum toxin, in treating focal spasticity of the upper limb caused by cerebrovascular accidents or traumatic brain injuries.
- It involved 210 patients divided into two groups; one received Relatox injections, while the other received Dysport. Both groups showed a reduction in spasticity over 12 weeks, with no significant differences between the two treatments.
- Various measurements were used to assess spasticity, disability, pain, and treatment satisfaction, and both medications were found to be effective, with a report on adverse events collected throughout the study.
Treatment with OnabotulinumtoxinA for Oromandibular Dystonia: A Systematic Review and Meta-Analysis.
Toxins (Basel)
December 2024
Department of Neurology, Tokushima University, Tokushima 770-8503, Japan.
Article Synopsis
- Oromandibular dystonia (OMD) is a condition causing muscle contractions in the jaw and related areas, and this study analyzed the effects of botulinum toxin (onabotulinumtoxinA) as a treatment.
- A meta-analysis of 26 studies with 1103 patients showed that 96.2% experienced a positive response to the injections, with 88.9% achieving significant improvement of over 50%.
- Although 17.8% of patients had adverse effects, mainly dysphagia (10.1%), the overall findings suggest that botulinum toxin is an effective treatment for OMD but further studies are needed for more conclusive results.
Integrating Telemedicine in Botulinum Toxin Type-A Treatment for Spasticity Management: Perspectives and Challenges from Italian Healthcare Professionals.
Toxins (Basel)
December 2024
Spasticity and Movement Disorders "ReSTaRt", Physical Medicine and Rehabilitation Section, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
(1) Background: Telemedicine is a vital tool for enhancing healthcare accessibility and outcomes at reduced costs. This study aimed to assess the usability of the Maia Connected Care telemedicine platform for managing spasticity in patients receiving botulinum toxin type-A, focusing on the perspectives of Italian physiatrists with expertise in this treatment. (2) Methods: Conducted from March 2023 to June 2023, this multicenter survey involved 15 Italian physicians who used the platform for teleconsultations.
View Article and Find Full Text PDFAre We Missing Something About the Maximum Dosing of Botulinum Toxin Type A1 in Adult and Pediatric Patients with Spasticity?
Toxins (Basel)
November 2024
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
Botulinum toxin type A1 is a first-line treatment for adult and pediatric spasticity. However, when considering the quantity of 150 kDa neurotoxin protein in relation to patient weight and the maximum recommended dose for treating adult and pediatric patients with spasticity, several concerns arise. First, the therapeutic margin (the ratio of the actual maximum quantity of toxin recommended for treating adult spasticity to its median lethal dose) appears to be relevant.
View Article and Find Full Text PDFThe Lack of Effect of Botulinum Toxin-A on Upper Limb Activity in Chronic Stroke: A Short Report from the InTENSE Trial.
Toxins (Basel)
November 2024
Alfred Health, Melbourne, VIC 3004, Australia.
Article Synopsis
- This study analyzed the effects of botulinum toxin-A on upper limb issues in chronic stroke survivors, focusing on those with significant spasticity.
- The research involved 71 stroke survivors and measured changes in various outcomes, including upper limb activity, spasticity, and grip strength, before and three months after treatment.
- Results showed no significant improvement in any of the measured outcomes, indicating that botulinum toxin-A may not be beneficial for improving upper limb function in this patient group with severe activity limitations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!